Genomic Vision and PolyAn Sign an Agreement for the Production and Supply of Coverslips
03 Octobre 2019 - 7:00AM
Business Wire
Regulatory News:
Genomic Vision (FR0011799907 - GV), a biotechnology
company developing molecular and Artificial Intelligence tools to
control quality and safety of genetically modified genome,
announced today the signature of a supply agreement with PolyAn in
the field of manufacturing and supply of coverslips.
The recent development of Life Science Research (LSR) product
line by Genomic Vision has increased the need for high quality
silanized glass coverslips. Together with the growing demand for
coverslips, it appeared necessary to secure the best surface
quality.
In order to address this challenge, Genomic Vision looked for a
new partner able to produce high quality coverslip to become its
manufacturing partner.
Florence Mahé, Head of R&D and manufacturing at Genomic
Vision, declared: “PolyAn is the right partner for Genomic Vision
for coverslip manufacturing: high quality standard, process scale
up capabilities and strong expertise in glass surface
functionalization. The Genomic Vision coverslip is a key consumable
without which DNA could not be combed correctly. Consumption of
coverslip has been constantly increasing these last years. In 2018,
more than 20.000 units have been used in the world.”
Fridtjof Lechhart, CEO of PolyAn, added: “We are very glad for
having set up this exclusive supply agreement with Genomic Vision.
With the development of the different promising assay in the LSR
field, such as in Quality Control and in DNA replication, we are
confident that we will be able to meet the demand, to increase the
batch size and therefore the production. We are also pleased to
participate in providing researchers, doctors and patient with high
quality and accurate results thanks to best quality surfaces to
stretch DNA strands.”
***
ABOUT GENOMIC VISION
Genomic Vision is a biotechnology company developing molecular
and Artificial Intelligence tools to control quality and safety of
genetically modified genome in particular in genome editing
technologies and biomanufacturing processes.
Genomic Vision proprietary molecular tools provide robust
quantitative measurements that are needed to enable high confidence
characterization of DNA alteration in the genome. These tools are
currently use for monitoring DNA replication in cancerous cell, for
early cancer detection and the diagnosis of genetic diseases.
Based near Paris, in Bagneux, the Company has approximately 30
employees. GENOMIC VISION is a public listed company listed in
compartment C of Euronext’s regulated market in Paris (Euronext: GV
- ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
ABOUT POLYAN
PolyAn is a nanotechnology company specialized in the
modification of surfaces using Molecular Surface Engineering (MSE).
Since 1996 PolyAn develops and manufactures consumables for
multiplex diagnostic and Life Science research.
PolyAn is certified according to DIN ISO 9001. PolyAn’s
production facilities also include a class 7 cleanroom.
Membre des indices CAC® Mid & Small et CAC®
All-Tradable
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 28, 2017, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191002005819/en/
Genomic Vision Aaron Bensimon Co-founder, Chairman &
CEO Tel.: +33 1 49 08 07 50 investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
Tel.: +33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024